Race Oncology Successfully Doses First Patient in Phase 1 Trial

Race Oncology Ltd. ( (AU:RAC) ) has issued an announcement.

Race Oncology announced the successful and safe dosing of the first patient with a combination of RC220 and doxorubicin in a Phase 1 clinical trial for advanced solid tumors. Conducted at Southside Cancer Care Centre, the trial aims to assess the safety, tolerability, and efficacy of this combination, with plans to expand to sites in Hong Kong and South Korea. This trial is significant for Race Oncology as it explores the potential of RC220 to offer improved treatment options with reduced cardiotoxicity, potentially enhancing its market position and impact on cancer treatment.

More about Race Oncology Ltd.

Race Oncology (ASX: RAC) is an ASX-listed clinical stage biopharmaceutical company focused on cancer care. Its lead asset, bisantrene, is an anticancer agent known for its therapeutic benefits and reduced cardiotoxicity compared to other anthracyclines. The company is advancing a reformulated version, RC220, to meet high unmet needs in oncology, particularly in anthracycline combinations.

Average Trading Volume: 121,283

Technical Sentiment Signal: Sell

Current Market Cap: A$196.3M

For an in-depth examination of RAC stock, go to TipRanks’ Overview page.